Glucoraphanin for Health & Longevity
Evidence Review created on 11/09/2026 using AI4L + evidence-mcp / Opus 5.5
Also known as: Sulforaphane Glucosinolate, SGS, 4-methylsulfinylbutyl glucosinolate, 4-(methylsulfinyl)butyl glucosinolate, TrueBroc
Motivation
Glucoraphanin is a natural plant compound stored in broccoli, and in especially large amounts in young broccoli sprouts and seeds. On its own it is inactive. When the plant is chewed, or when gut bacteria act on it, it turns into sulforaphane, a compound that switches on the body’s own protective and detoxifying enzymes. Because glucoraphanin is stable and easy to put into capsules, it is the form that most broccoli-based supplements actually contain.
Interest began in the 1990s, when laboratory work at Johns Hopkins University singled out sulforaphane as the protective-enzyme trigger in broccoli and turned attention to sprouts and seeds as concentrated sources. Since then, glucoraphanin-rich drinks, capsules and specially bred broccoli have been tested in people for liver health, memory and thinking speed in older adults, and the clearance of air pollutants.
This review examines what human studies show about taking glucoraphanin: how much of it the body turns into its active form, which benefits and risks have been measured, how it is dosed and sourced, and how it compares with sulforaphane-based products, for adults pursuing health and longevity.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
The items below give a high-level overview of glucoraphanin, its conversion into sulforaphane, and the practical choices this conversion raises.
-
Sulforaphane - Rhonda Patrick
An in-depth overview with a dedicated glucoraphanin and myrosinase (the plant enzyme that converts it) section, covering Nrf2 (a master switch for protective genes) activation and human trials in autism, air pollution and diabetes.
-
New Strategy to Reduce Cancer Risk - Edward Sanford
Explains why glucoraphanin-only supplements convert poorly into sulforaphane and argues for pairing glucoraphanin with myrosinase; written for Life Extension, which sells such a product, so parts are promotional.
-
The Powerful Health Benefits of Sulforaphane - Chris Kresser
Podcast episode on sulforaphane, the active product of glucoraphanin, covering variable gut conversion and supplement choice; Kresser promotes a commercial broccoli product in the show notes.
-
The Challenges of Designing and Implementing Clinical Trials With Broccoli Sprouts… and Turning Evidence Into Public Health Action - Fahey & Kensler, 2021
Narrative review by the Johns Hopkins investigators behind most glucoraphanin trials, explaining dose selection, placebo design and why glucoraphanin and sulforaphane formulations give different exposures.
-
Glucoraphanin conversion into sulforaphane and related compounds by gut microbiota - Dmytriv et al., 2025
Narrative review of how gut bacteria convert glucoraphanin into sulforaphane and related compounds, why differences in gut bacteria change conversion efficiency, and how sulforaphane in turn may support the gut barrier.
Sulforaphane is covered in a Huberman Lab episode featuring Rhonda Patrick, whose content is already listed, and only briefly in Andrew Huberman’s Huberman Lab microplastics episode, within a broader detoxification segment. No dedicated content on glucoraphanin or sulforaphane was found from Peter Attia or Lifespan.io: their site searches and web searches returned no relevant articles.
Grokipedia
-
An AI-generated encyclopedia entry covering glucoraphanin’s chemistry, plant sources, conversion by plant and gut enzymes, and a summary of clinical findings; useful for background, not as primary evidence.
Examine
No Examine article on glucoraphanin exists; a direct search of examine.com for “glucoraphanin” returned no results.
ConsumerLab
No ConsumerLab article dedicated to glucoraphanin exists; a direct search of consumerlab.com for “glucoraphanin” returned only brief mentions inside broader answers on memory, arthritis and fatty liver supplements.
Systematic Reviews
No systematic review or meta-analysis has examined glucoraphanin itself; the reviews below cover sulforaphane, its active product, or broccoli and other Brassica vegetables, its food sources.
-
Meta-analysis of six sulforaphane trials (333 participants) in autism: social responsiveness improved at 4–10 weeks, without excess adverse events.
-
Efficacy and safety of sulforaphane in schizophrenia: a systematic review and meta-analysis of randomized controlled trials - Kassar et al., 2025
Four sulforaphane trials (369 patients) in schizophrenia: no effect on total symptoms or cognition; small, transient gain in negative symptoms (reduced drive and expression).
-
Broccoli Consumption and Risk of Cancer: An Updated Systematic Review and Meta-Analysis of Observational Studies - Baladia et al., 2024
Thirty-five observational studies link higher broccoli intake with lower cancer risk; indirect for glucoraphanin, because broccoli contains many other compounds.
-
Efficacy and tolerability of sulforaphane in the therapeutic management of cancers: a systematic review of randomized controlled trials - ElKhalifa et al., 2023
Eight cancer trials, including glucoraphanin capsules and soups: some tissue biomarkers changed, prostate-specific antigen results were inconsistent, and adverse events did not exceed controls.
-
Do Brassica Vegetables Affect Thyroid Function?-A Comprehensive Systematic Review - Galanty et al., 2024
Principal-risk review: 123 laboratory, animal and human studies indicate Brassica intake does not impair thyroid function when iodine intake is adequate.
Mechanism of Action
Glucoraphanin is a glucosinolate (a sulfur-containing plant compound bound to a sugar) and is inert until it is split. Plant myrosinase, released when raw tissue is chewed, or bacterial thioglucosidases (sugar-cleaving enzymes) in the colon convert it into sulforaphane, an isothiocyanate (a reactive sulfur compound) (Fahey 2012); heat-treated extracts depend on the bacterial route, a process abolished by enteric antibiotics and bowel cleansing (Fahey 2012).
- Primary pathway: Sulforaphane binds Keap1 (a protein that keeps Nrf2 inactive), freeing Nrf2 to switch on genes for NQO1 (an enzyme that neutralizes reactive quinones), glutathione S-transferases (GSTs, enzymes attaching glutathione to toxins) and glutathione synthesis.
- Selectivity: Sulforaphane induces these protective enzymes without inducing the aryl hydrocarbon receptor-dependent cytochromes P450 (enzymes, controlled by a toxin-sensing receptor, that can activate carcinogens) (Zhang 1992).
- Secondary actions: In laboratory models it also dampens NF-κB (a central inflammation switch) and inhibits histone deacetylases (HDACs, enzymes that silence genes).
- Competing views: Benefits may reflect hormesis (a protective response to mild chemical stress) rather than antioxidant action, and Nrf2 activation can also protect established tumors.
- Conversion: Urinary recovery of sulforaphane metabolites was about 5% of a glucoraphanin dose versus 70% for preformed sulforaphane (Egner 2011).
- Metabolism and half-life: Absorbed isothiocyanates are conjugated with glutathione and sequentially metabolized to mercapturic acids (excreted detoxification products) (Shapiro 2001); they peak in plasma at 1 hour (Ye 2002) with a half-life of 1.77 hours (Ye 2002).
- Distribution: Sulforaphane reached prostate tissue after glucoraphanin supplements (Livingstone 2022).
Historical Context & Evolution
- Original role: Glucoraphanin evolved as a plant defense chemical; broccoli was eaten as food, and the compound had no medical use before chemoprevention (cancer prevention with natural or drug agents) research began.
- Discovery (1992): Paul Talalay’s Johns Hopkins group isolated sulforaphane from broccoli as a major inducer of protective detoxication enzymes in cell and mouse assays (Zhang 1992).
- Sprouts (1997): Three-day-old broccoli sprouts were found to contain 10–100 times more glucoraphanin than mature plants (Fahey 1997), and sprout extracts reduced mammary tumors in carcinogen-treated rats (Fahey 1997). This finding launched sprout and seed-extract products.
- Human trials (2005–2019): Trials in Qidong, China, tested glucoraphanin-rich beverages against dietary and airborne carcinogens; the first found no overall effect on markers of DNA damage from aflatoxin (a mold toxin in food) (Kensler 2005), while a later one increased excretion of conjugates of benzene and acrolein (a toxic combustion product) (Egner 2014).
- Bioavailability shift: The finding that preformed sulforaphane is far better absorbed than glucoraphanin moved research toward glucoraphanin-plus-myrosinase products (Egner 2011).
- Breeding and sponsorship: A high-glucoraphanin broccoli was bred and patented at the John Innes Centre in the United Kingdom, with a trial investigator named as inventor (Armah 2015), and the Japanese food company Kagome funded later liver trials (Kikuchi 2015; Satomi 2022).
- Current standing: Mechanistic support remains strong, but small trials, mixed results and null findings in diabetes and pollutant markers mean the question is still open in both directions.
Expected Benefits
High 🟩 🟩 🟩
No benefit reaches High: the glucoraphanin trials with clinical or validated surrogate endpoints each come from a single sponsor or research group, and the broader findings rest on sulforaphane products, whole broccoli or observational data.
Medium 🟩 🟩
Lower Liver Enzymes
Glucoraphanin capsules lowered ALT (alanine aminotransferase, an enzyme that leaks from stressed liver cells) in two Japanese placebo-controlled trials, both funded by the food company Kagome and co-authored by its employees. In men with fatty liver, Kagome’s capsules lowered ALT from baseline after 2 months, with no significant change on placebo (Kikuchi 2015). In healthy middle-aged adults with high-normal values, 60 mg/day for 24 weeks lowered ALT versus placebo (Satomi 2022), without changing serum glutathione (Satomi 2022). The proposed mechanism is reduced oxidative stress.
Magnitude: At 24 weeks, median ALT was 29.0 U/L with glucoraphanin versus 30.0 U/L with placebo, from baselines of 36.0 and 35.0 U/L (Satomi 2022).
Faster Processing Speed in Older Adults
In healthy older adults, 30 mg/day glucoraphanin for 12 weeks improved processing speed and working memory compared with placebo, using capsules prepared by Kagome (Nouchi 2021). A second 12-week trial found improved processing speed and reduced negative mood versus placebo (Nouchi 2022). A Kagome-funded 42-month pilot of glucoraphanin with added mustard-seed myrosinase (indirect evidence) in 26 adults with memory impairment found greater improvement in a memory index than placebo (Shimizu 2026), without a difference in progression to mild cognitive impairment (Shimizu 2026). All three trials share one supplier.
Magnitude: Over 12 weeks, symbol-search (processing speed) scores rose 1.99 points with glucoraphanin versus 1.29 points with placebo (adjusted p = 0.03, p being the probability of a difference this large arising by chance; no confidence interval, the range likely to contain the true value, reported) (Nouchi 2022).
Low 🟩
Lower LDL Cholesterol
In two randomized trials, 400 g/week of high-glucoraphanin broccoli for 12 weeks lowered LDL (low-density lipoprotein, a cholesterol carrier linked to heart disease) cholesterol more than standard broccoli (Armah 2015). Evidence is indirect (whole cooked broccoli). The broccoli is patented, and an investigator is a named inventor.
Magnitude: LDL fell 7.1% (95% CI 1.8% to 12.3%; CI is the confidence interval) on high-glucoraphanin broccoli versus 1.8% on standard broccoli in study 1 (Armah 2015), and 5.1% versus 2.5% in study 2 (Armah 2015); with both studies combined, the LDL reduction was significantly greater on high-glucoraphanin broccoli (p = 0.031) (Armah 2015).
Modestly Lower Fasting Glucose ⚠️ Conflicted
A broccoli sprout extract delivering sulforaphane lowered fasting glucose in prediabetes over 12 weeks (Dwibedi 2025); evidence is indirect (preformed sulforaphane). A broccoli sprout extract did not change glucose or HbA1c (three-month average blood sugar) in diabetes with kidney disease (Avesani 2026). Net: small, inconsistent effect.
Magnitude: Fasting glucose fell 0.2 mmol/L more than with placebo (95% CI 0.01 to 0.44) (Dwibedi 2025).
Reduced Helicobacter pylori Colonization
In 48 infected adults, 70 g/day of broccoli sprouts (420 µmol glucoraphanin) for 8 weeks lowered breath-test and stool markers of H. pylori (a stomach bacterium linked to stomach inflammation and cancer), unlike alfalfa sprouts (Yanaka 2009); values returned to baseline after stopping (Yanaka 2009). Evidence is indirect (fresh sprouts).
Magnitude: 8 of 25 participants on broccoli sprouts fell below the stool-antigen cutoff at 8 weeks (Yanaka 2009), none below the breath-test cutoff (Yanaka 2009); the alfalfa group showed no significant change in stool antigen; not compared between groups (Yanaka 2009).
Lower Cancer Risk
In a meta-analysis of 12 cohort and 23 case-control studies, higher broccoli intake was associated with lower cancer risk (Baladia 2024). Evidence is indirect: broccoli supplies many compounds besides glucoraphanin, and observational data cannot exclude healthier habits among broccoli eaters.
Magnitude: Cohort studies gave an RR (relative risk, the risk with high intake divided by the risk with low intake) of 0.89 (95% CI 0.82 to 0.96) (Baladia 2024); case-control studies gave an OR (odds ratio, a similar ratio based on the odds of having cancer) of 0.64 (95% CI 0.58 to 0.70) (Baladia 2024).
Autism Symptom Relief ⚠️ Conflicted ⭕️ Not Central to Health & Longevity
Sulforaphane reduced social responsiveness scores in a meta-analysis of autism trials (Long 2025). In children, manufacturer-supplied glucoraphanin-plus-myrosinase tablets did not beat placebo on the primary autism rating (Zimmerman 2021). It bears on neurodevelopment, not aging; evidence is indirect (preformed sulforaphane; added myrosinase). Net: modest, unconfirmed benefit.
Magnitude: Social Responsiveness Scale scores fell versus control with an SMD (standardized mean difference, the gap between groups expressed in standard-deviation units) of −0.98 (95% CI −1.69 to −0.28) at 4–5 weeks (Long 2025).
Fewer Negative Symptoms in Schizophrenia ⚠️ Conflicted ⭕️ Not Central to Health & Longevity
A meta-analysis of four sulforaphane trials found a small improvement in negative symptoms (reduced drive and emotional expression) at 12 weeks that was not maintained (Kassar 2025), and no cognitive benefit (Kassar 2025). It bears on psychiatric care, not aging; evidence is indirect (preformed sulforaphane). Net: weak.
Magnitude: Negative symptoms showed a mean difference of −1.06 points versus control (95% CI −1.95 to −0.16) at 12 weeks (Kassar 2025).
Speculative 🟨
Faster Clearance of Airborne Carcinogens ⚠️ Conflicted
A glucoraphanin-rich beverage raised urinary benzene and acrolein conjugates versus placebo (Egner 2014). An earlier glucoraphanin infusion did not change markers of phenanthrene (an air-pollutant hydrocarbon) (Kensler 2005). These markers are unvalidated. Net: uncertain.
Slower Prostate Cancer Progression
In men on active surveillance (monitoring without treatment), 12 months of glucoraphanin-rich broccoli soup attenuated cancer-associated gene-expression changes in prostate tissue (Traka 2019). Evidence is indirect (whole broccoli); gene expression is unvalidated, progression unassessed.
Benefit-Modifying Factors
- Gut bacteria: Without plant myrosinase, conversion of glucoraphanin varies from about 1% to more than 40% between people (Fahey 2012); glucose responders carried more of a Bacteroides gene needed for conversion (Dwibedi 2025).
- GSTM1 genotype: People lacking GSTM1 (a gene for a glutathione-attaching detoxification enzyme) excrete sulforaphane metabolites faster and reach slightly higher plasma levels (Gasper 2005); whether this changes clinical benefit is unknown.
- Baseline biomarkers: Liver-enzyme effects were shown in adults with high-normal ALT (Satomi 2022); glucose lowering was larger in prediabetic participants with mild obesity, low insulin resistance and reduced insulin secretion (Dwibedi 2025).
- Sex: Sex had negligible effects on conversion (Fahey 2019); no trial reports sex-specific benefits.
- Body mass and stomach acid: Greater body mass correlated with lower conversion efficiency (Fahey 2019), and acid-suppressing medication raised conversion from myrosinase-containing extracts (Fahey 2019).
- Age: Cognitive benefits were reported in adults up to 90 years old (Shimizu 2026); age had negligible effects on conversion (Fahey 2019).
Potential Risks & Side Effects
High 🟥 🟥 🟥
No risk reaches High: adverse-event data come from small trials not powered for harms, with no replicated documented adverse event.
Medium 🟥 🟥
No risk reaches Medium: adverse events in glucoraphanin trials were few, mild and close to placebo rates, and the clearer gastrointestinal signal comes from sulforaphane-delivering extracts, which are indirect evidence.
Low 🟥
Gastrointestinal Discomfort and Taste Intolerance ⚠️ Conflicted
In a randomized trial, glucoraphanin-rich beverages caused mild stomach discomfort and unacceptable taste at rates close to placebo (Egner 2014). A sulforaphane-yielding extract caused more loose stools and nausea than placebo (Dwibedi 2025); this is indirect. Irritant isothiocyanates are the likely cause. Net: no clear excess with glucoraphanin itself.
Magnitude: Mild adverse events occurred in 4.1% on the broccoli sprout beverage versus 2.8% on placebo (Egner 2014); loose stools occurred in 8 of 44 on the extract versus 1 of 45 on placebo (Dwibedi 2025).
Thyroid Suppression ⚠️ Conflicted
Glucosinolates and isothiocyanates are suspected goitrogens (substances that impair thyroid hormone production), as a systematic review notes (Galanty 2024). In a 12-week randomized trial, a beverage rich in glucoraphanin and sulforaphane did not affect thyroid hormones or thyroid autoimmunity (Chartoumpekis 2019). Net: no human harm shown.
Magnitude: Thyroid-stimulating hormone, free thyroxine (the main circulating thyroid hormone) and thyroglobulin (a thyroid protein) were not affected after 84 days in 45 women; the source reports no between-group figure (Chartoumpekis 2019).
Insomnia, Irritability and Isolated Seizure Reports ⚠️ Conflicted
In children with autism, glucoraphanin-plus-myrosinase side effects included insomnia, irritability and taste intolerance (Zimmerman 2021); one child’s seizure, a month after stopping, was judged unrelated (Zimmerman 2021). A meta-analysis found no excess adverse events with sulforaphane (Long 2025). Evidence is indirect (added myrosinase; preformed sulforaphane). Net: uncommon, unconfirmed.
Magnitude: Not quantified in available studies. The trial described insomnia and irritability as rare without reporting their rates by group (Zimmerman 2021).
Speculative 🟨
Protection of Established Tumors
Nrf2 activation shields cells from oxidative and chemical stress, and some cancers rely on constant Nrf2 activity to resist chemotherapy. Sulforaphane could, in theory, support such cells. No human data exist; the basis is mechanistic.
Pro-Oxidant Effects at High Doses
At high concentrations in cell culture, sulforaphane depletes glutathione and becomes toxic to cells, a two-phase dose response. No human data exist at supplement doses; the basis is mechanistic.
Risk-Modifying Factors
- GSTM1 and GSTT1 genotypes: GSTM1-null people clear sulforaphane metabolites faster (Gasper 2005); GSTT1-positive people (carriers of another glutathione S-transferase gene) excreted more benzene conjugate regardless of treatment (Egner 2014). No genotype has been linked to adverse effects.
- Baseline thyroid and iodine status: Brassica intake appears safe for the thyroid when iodine intake is adequate, according to a systematic review (Galanty 2024); people with low iodine intake or a raised baseline TSH (thyroid-stimulating hormone, which drives thyroid output) lack trial data.
- Sex: No sex-based differences in adverse effects are reported; the thyroid safety analysis included only women (Chartoumpekis 2019).
- Digestive conditions: People with reflux or irritable bowel may be more prone to the loose stools, nausea and reflux seen with sulforaphane-yielding extracts (inferred from Dwibedi 2025; no subgroup data).
- Age: Adults aged 63–90 took 30 mg/day for 42 months without severe intervention-related adverse events (Shimizu 2026); multiple medications in older age increase the relevance of enzyme-induction interactions.
- Cancer history: People with active or recent cancer carry the theoretical tumor-protection concern (inferred from Nrf2 biology; no human data).
Key Interactions & Contraindications
Documented interactions:
- Proton pump inhibitors (acid-reducing drugs such as omeprazole, esomeprazole): With glucoraphanin-plus-myrosinase extracts, more sulforaphane was excreted after participants started omeprazole (Fahey 2019), and enteric coating also raised conversion (Fahey 2019). Consequence: higher, less predictable exposure; consistent dosing limits swings.
- Oral antibiotics (amoxicillin, ciprofloxacin): When bowel bacteria were reduced by cleansing and antibiotics, conversion of glucosinolates became negligible (Shapiro 1998). Consequence: little sulforaphane from glucoraphanin-only products during a course; switching to a myrosinase-containing product bypasses gut conversion.
- CYP1A2 substrates (caffeine, theophylline, clozapine, tizanidine): In a meta-analysis of diet trials, cruciferous-vegetable (cabbage-family) diets increased CYP1A2 (a liver enzyme that clears these drugs) activity by 20–40% (Eagles 2020). Consequence: possibly lower drug levels; glucoraphanin extracts untested; drug-level checks for narrow-margin drugs.
- UGT1A1 substrates (irinotecan, raltegravir): Cruciferous feeding lowered serum bilirubin, a marker of UGT1A1 (an enzyme that attaches glucuronic acid to bilirubin and drugs) activity (Navarro 2009). Consequence: possibly faster drug clearance; extracts untested; a drug-level check 2–4 weeks after starting detects under-dosing.
- CYP3A4 substrates (midazolam, simvastatin, tacrolimus): In a randomized crossover trial, broccoli sprout extract (450 µmol sulforaphane daily) did not change the activity of CYP3A4 (the main drug-metabolizing liver enzyme), measured with midazolam (Poulton 2013). Consequence: no interaction found; glucoraphanin-only products untested.
- Mustard-seed myrosinase (supplement): In a trial led by an employee of glucoraphanin supplier Brassica Protection Products, adding mustard seed powder to a glucoraphanin extract raised sulforaphane bioavailability from 18.6% to 39.8% (Mastaloudis 2026). Consequence: doubled exposure, possibly more gastrointestinal effects; lower doses offset it.
- Curcumin (supplement): Glucoraphanin and curcumin each induced NQO1 in skin (Chien 2025); the combination gave 3.6-fold induction versus 3.1-fold for glucoraphanin alone (Chien 2025), and supplements were well tolerated (Chien 2025). Consequence: additive protective-enzyme induction, no adverse interaction found.
Theoretical interactions (inferred from mechanism, not studied in humans):
- Glucose-lowering drugs (metformin, insulin, glipizide): Inferred from sulforaphane’s suppression of liver glucose production. Consequence: additive glucose lowering and possible hypoglycemia (abnormally low blood sugar); glucose checks during the first weeks mitigate it.
- Acetaminophen: Inferred from induction of glutathione-conjugating enzymes, which handle acetaminophen’s toxic metabolite. Consequence: altered metabolism of uncertain direction; a trial uses acetaminophen as a probe (NCT06009926).
- Chemotherapy and radiotherapy (doxorubicin, cisplatin): Inferred from Nrf2-driven protection that could also shield tumor cells. Consequence: possibly reduced treatment efficacy; coordination with the oncology team before use mitigates it.
- Other isothiocyanate supplements (sulforaphane, moringa extracts): Inferred from additive isothiocyanate load. Consequence: more gastrointestinal discomfort; counting total daily isothiocyanate yield avoids stacking.
Populations who should avoid Glucoraphanin:
- People with mustard allergy, for products containing mustard-seed myrosinase (inferred from the allergen source; no product-specific data).
- Pregnant or breastfeeding women at supplement doses (inferred from isothiocyanate induction of detoxification enzymes, whose effect on the fetus or infant is unknown; no human data).
- People receiving chemotherapy or radiotherapy, unless their oncology team agrees (inferred from Nrf2-mediated protection of tumor cells; no human data).
- People with untreated hypothyroidism (underactive thyroid) and iodine deficiency (inferred from the goitrogen concern; no harm was found with adequate iodine in a systematic review (Galanty 2024)).
Risk Mitigation Strategies
Doses and timings below follow common practice unless cited.
- Start at trial doses: Beginning at 30 mg/day, the dose used in the cognition trials (Nouchi 2021; Nouchi 2022; Shimizu 2026), before higher intakes limits gastrointestinal discomfort and taste intolerance.
- Take with a light meal: Taking capsules with a light meal rather than on an empty stomach reduces nausea and stomach discomfort.
- Thyroid check for at-risk users: For people with thyroid disease or low iodine intake, TSH at baseline and after 3 months detects suppression; a TSH above the laboratory reference range is a reason to pause and seek medical advice.
- Consistent acid-suppressant timing: Keeping proton pump inhibitor and supplement timing unchanged from day to day prevents swings in sulforaphane exposure.
- Drug-level checks: For narrow-margin CYP1A2 or UGT1A1 substrates such as clozapine or theophylline, a drug level 2–4 weeks after starting prevents under-dosing from enzyme induction.
- Glucose checks on diabetes drugs: Home glucose checks daily for the first 2 weeks prevent unnoticed hypoglycemia with insulin or sulfonylureas (insulin-releasing drugs such as glipizide).
- Pause for behavioral effects: Insomnia or irritability, reported in a pediatric trial (Zimmerman 2021), is a reason to stop, which prevents ongoing sleep loss and behavioral disturbance.
- Pause around cancer treatment: Stopping from diagnosis through the end of chemotherapy or radiotherapy avoids the theoretical tumor-protection risk.
Therapeutic Protocol
Doses below are cited to their source; timing, splitting, titration and other uncited parameters reflect common practice.
- Glucoraphanin-only capsules: 30 mg/day in the 12-week cognition trials (Nouchi 2021; Nouchi 2022) and 60 mg/day (137.1 µmol) for 24 weeks in the liver trial (Satomi 2022); this approach was popularized by Kagome-sponsored research in Japan.
- Beverage regimen (Johns Hopkins group): 600 µmol glucoraphanin plus 40 µmol sulforaphane daily for 12 weeks (Egner 2014); the effective dose yielded about 25 µmol of urinary sulforaphane metabolites per day (Chen 2019).
- Glucoraphanin plus myrosinase: Adding mustard-seed myrosinase doubled bioavailability (Mastaloudis 2026); a Johns Hopkins-linked trial dosed tablets at about 2.2 µmol/kg/day of sulforaphane yield (Zimmerman 2021). Life Extension, which sells such a product, promotes this approach (Life Extension article).
- Competing approaches: Glucoraphanin alone, glucoraphanin with myrosinase, fresh sprouts and preformed sulforaphane have never been compared on clinical outcomes; preformed sulforaphane is far better absorbed than glucoraphanin alone (Egner 2011).
- Food alternative: Fresh sprouts contain 10–100 times more glucoraphanin than mature broccoli (Fahey 1997), and thorough chewing raises excretion of isothiocyanate metabolites (Shapiro 2001).
- Time of day: Gut conversion of glucosinolates was greater during the day than at night (Fahey 2012); morning or midday dosing is common practice.
- Half-life: Absorbed isothiocyanates have a plasma half-life of 1.77 hours (Ye 2002); glucoraphanin’s gradual gut conversion gives considerably slower elimination (Egner 2011).
- Single or split dose: Most efficacy trials used once-daily dosing; the phase I safety study gave doses at 8-hour intervals (Shapiro 2006). Glucoraphanin’s slow conversion makes once-daily dosing practical.
- Genetic variants: GSTM1-null status speeds sulforaphane excretion (Gasper 2005); no genotype-based dose adjustment has been tested.
- Sex: Sex had negligible effects on conversion (Fahey 2019); trials used the same dose for women and men.
- Age: Adults aged 63–90 used 30 mg/day for 42 months (Shimizu 2026); the same dose served younger older adults.
- Baseline biomarkers: Benefits appeared in people with high-normal ALT (Satomi 2022) or prediabetes (Dwibedi 2025); people with normal values have less room to improve.
- Pre-existing conditions: Higher body mass lowers conversion (Fahey 2019), so heavier people and those recently given antibiotics obtain less sulforaphane from glucoraphanin-only products.
Discontinuation & Cycling
- Duration: Glucoraphanin is used as long-term prevention rather than a short course; the longest trial ran 42 months (Shimizu 2026).
- Withdrawal effects: None are reported; effects simply fade, as H. pylori markers returned to baseline 2 months after sprouts were stopped (Yanaka 2009).
- Tapering: Not needed; there is no dependence or rebound, so use can stop at once.
- Cycling: Not needed for efficacy: sulforaphane bioavailability did not decline over 12 weeks of daily dosing (Egner 2014).
Sourcing and Quality
- Know the form: Products contain glucoraphanin alone (relies on gut bacteria), glucoraphanin plus myrosinase (usually from mustard seed or broccoli), or stabilized sulforaphane; labels often say “sulforaphane glucosinolate” for glucoraphanin.
- Standardized ingredient: A commercial glucoraphanin supplement made from broccoli seed extract by Brassica Protection Products, which funded the analysis, yielded urinary sulforaphane metabolites equivalent to an equimolar boiled sprout extract (Fahey 2015).
- Brands used in trials: Avmacol tablets (glucoraphanin plus myrosinase) in a Johns Hopkins-linked trial (Zimmerman 2021), BroccoMax in a prostate tissue study (Livingstone 2022) and broccoli sprout extract capsules in a Kagome-supported Japanese trial (Satomi 2022).
- What to look for: Third-party seals from USP (United States Pharmacopeia) or NSF International and a certificate of analysis stating glucoraphanin in mg or µmol per dose, and, for combination products, active myrosinase.
- Heat sensitivity: Myrosinase is destroyed by cooking (Okunade 2018), so myrosinase products lose their advantage when stirred into hot drinks or food.
Practical Considerations
- Time to effect: Pollutant-excretion changes appeared rapidly (Egner 2014); processing-speed changes were measured at 12 weeks (Nouchi 2021), and liver-enzyme differences at 24 weeks (Satomi 2022).
- Common pitfall, equating precursor and product: Treating a glucoraphanin dose as a sulforaphane dose greatly overstates exposure, given 5% versus 70% urinary recovery (Egner 2011).
- Common pitfall, heat: Mixing powders into hot water or cooking with them inactivates myrosinase.
- Regulatory status: In the United States, glucoraphanin is sold as a dietary supplement regulated under the Dietary Supplement Health and Education Act of 1994, with manufacturers responsible for safety and labeling (FDA Dietary Supplements page); it is not an approved drug.
- Accessibility: Capsules, tablets, seed powders and sprouting seeds are widely available without prescription; cost is moderate.
Interaction with Foundational Habits
- Sleep: No direct effect in adults. Insomnia was reported in children with autism (Zimmerman 2021); morning dosing fits the greater daytime gut conversion (Fahey 2012) and keeps any stimulation away from bedtime.
- Nutrition: Potentiating. Mustard powder added to cooked broccoli raised urinary sulforaphane metabolites more than fourfold (Okunade 2018); raw cruciferous foods such as radish or rocket also supply myrosinase. Adequate iodine intake offsets the theoretical thyroid concern.
- Exercise: None shown. Two weeks of high-glucoraphanin broccoli powder did not change recovery from eccentric (muscle-lengthening) exercise damage (Cesanelli 2026); there is no evidence of blunted training adaptation, and timing around workouts appears unimportant.
- Stress management: Indirect. Negative mood decreased compared with placebo in older adults (Nouchi 2022); no study has measured cortisol (the main stress hormone) or the physiological stress response.
Monitoring Protocol & Defining Success
Before starting, a baseline panel documents the markers glucoraphanin is expected to change, namely ALT, GGT (gamma-glutamyl transferase, a liver enzyme), LDL cholesterol and fasting glucose, and, for people with thyroid disease or low iodine intake, TSH as a safety check. People taking narrow-margin CYP1A2 or UGT1A1 drugs also record a baseline drug level.
Ongoing monitoring follows a cadence of 12 weeks, the length of most trials, then 24 weeks, when liver-enzyme differences emerged (Satomi 2022), then every 6–12 months while use continues. Thyroid-stimulating hormone is repeated at 3 months in at-risk users. Success is defined as a sustained fall from one’s own baseline in ALT or LDL cholesterol, or a stable or improving glucose, without gastrointestinal, sleep or thyroid problems. Because conversion differs greatly between people, an unchanged panel after 24 weeks may reflect low conversion rather than true non-response.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| ALT | About 7–55 U/L (standard reference range) | Expected to change: fell in glucoraphanin trials | Laboratory ranges vary; no fasting needed; alcohol and heavy exercise in the prior 48 hours raise it |
| GGT | About 8–61 U/L (standard reference range) | Expected to change: trended lower with glucoraphanin | Sensitive to alcohol and oxidative stress; best paired with ALT |
| LDL cholesterol | No established target for glucoraphanin use; track change from own baseline | Expected to change: fell with high-glucoraphanin broccoli | Fasting lipid panel preferred; same laboratory each time |
| Fasting glucose | 70–99 mg/dL (standard reference range) | Expected to change modestly in prediabetes | 8–12-hour fast; morning draw; pair with HbA1c every 6 months |
| TSH | 0.45–5.33 mIU/L (standard reference range) | Safety check: a rise prompts a pause | Reference range as used in Chartoumpekis 2019; morning draw; pair with free thyroxine if abnormal |
Qualitative markers:
- Gastrointestinal comfort (stool consistency, nausea, bloating)
- Sleep quality and any new irritability
- Mental processing speed and clarity in daily tasks
- Mood and sense of energy
Emerging Research
- Smoker detoxification trial (NCT05121051): A National Cancer Institute phase 2 trial of Avmacol ES in about 135 heavy smokers measures benzene and acrolein detoxification over 12 weeks; primary completion is expected January 2027. A positive result would extend pollutant findings to smokers; a null result would weaken the detoxification case.
- Mild cognitive impairment trial (NCT07334366): A 12-week Korean trial of broccoli sprout extract in about 100 adults aged 50–85 uses a computerized cognitive score as primary endpoint; completion is expected December 2026. A positive result would be the first non-Kagome cognitive replication; a null result would weaken the cognition item.
- Melanoma prevention trial (NCT07040280): A US cancer cooperative group phase 2 trial of sulforaphane in about 120 people with atypical moles and prior melanoma measures change in mole area at 12 months; primary completion expected March 2031. A positive result would give a first clinical prevention signal; a null result would weaken chemoprevention claims.
- Psychosis prevention trial (NCT03932136): A Chinese phase 3 trial of sulforaphane in about 300 people aged 15–45 at clinical high risk of psychosis measures conversion to psychosis over 2 years; completion is expected December 2026. A positive result would strengthen the schizophrenia item; a null result would weaken it.
- Firefighter detoxification trial (NCT06009926): A phase 2 trial of broccoli seed and sprout extract in 72 firefighters reached primary completion in February 2026; no results are posted. Positive results would support occupational detoxification use; null results would weaken it.
- Neurodegenerative disease trial (NCT07360977): An open-label Italian trial of myrosinase-activated glucoraphanin in about 300 patients with Parkinson’s disease, multiple sclerosis or pediatric neuromuscular disease reached primary completion in October 2026; no results are posted. Positive results would justify blinded trials; null results would weaken neuroprotection claims.
- Responder prediction: Gut-bacterial conversion genes predicted glucose response (Dwibedi 2025) and conversion (Mastaloudis 2026); stool testing could identify likely responders and explain inconsistent trial results.
- Longer independent cognition trials: The 42-month pilot (Shimizu 2026) had only 19 completers; larger trials without sponsor involvement could confirm or overturn the cognitive signal.
- Evidence that could weaken the case: Null results in diabetes with kidney disease (Avesani 2026) and in muscle recovery (Cesanelli 2026) show that several proposed benefits have not held in controlled tests.
Conclusion
Glucoraphanin is the stable plant precursor of sulforaphane, and its value depends on how much of it a person’s gut bacteria, or an added plant enzyme, turn into the active compound. That conversion varies greatly between people, which helps explain why results differ from study to study.
For health-focused adults, the most direct human evidence points to small improvements in liver enzyme levels and in mental processing speed among older adults. Both rest on a handful of studies supported by one food company, so they are promising rather than established. Lower cholesterol, slightly lower blood sugar, less infection with a stomach-ulcer bacterium and lower cancer risk come mainly from whole broccoli, sprouts or ready-made sulforaphane, which makes them indirect, and some controlled studies found no blood-sugar effect. Faster clearance of air pollutants and fewer cancer-linked gene changes in prostate tissue are shown only through laboratory markers.
The side-effect profile appears mild: occasional stomach upset and taste complaints and, in children, sleep and mood changes, with no thyroid harm found in a controlled study. Theoretical concerns remain about shielding existing tumors and about changes in how some medicines are processed.
The evidence base is small and short, and much of it was funded by companies or inventors with a stake in broccoli products. Glucoraphanin appears to be a low-risk way to raise the body’s own protective enzyme activity, while its long-term effects on health and lifespan in people remain unmeasured.